Chilton Capital Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Chilton Capital Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$12.9K	Sell	26 -32	-55%	-$14.2K	﹤0.01%	443
2026 Q1	$25.9K	Buy	58 +57	+5,700%	+$26.6K	﹤0.01%	392
2025 Q4	$454	Buy	+1	New	+$431	﹤0.01%	644
2025 Q1	–	Sell	-13	Closed	-$5.24K	–	595
2024 Q4	$5.24K	Buy	+13	New	+$6.03K	﹤0.01%	491
2022 Q1	–	Sell	-89	Closed	-$20K	–	606
2021 Q4	$20K	Buy	+89	New	+$17.3K	﹤0.01%	422
2016 Q3	–	Sell	-31,875	Closed	-$2.74M	–	166
2016 Q2	$2.74M	Sell	31,875 -22,886	-42%	-$1.98M	0.27%	83
2016 Q1	$4.35M	Sell	54,761 -5,419	-9%	-$490K	0.44%	73
2015 Q4	$7.57M	Sell	60,180 -27,260	-31%	-$3.29M	0.79%	48
2015 Q3	$9.11M	Buy	87,440 +23,966	+38%	+$3.08M	0.94%	43
2015 Q2	$7.84M	Sell	63,474 -1,167	-2%	-$147K	0.74%	60
2015 Q1	$7.63M	Sell	64,641 -3,788	-6%	-$454K	0.77%	55
2014 Q4	$8.13M	Buy	68,429 +29,349	+75%	+$3.31M	0.83%	48
2014 Q3	$4.39M	Buy	+39,080	New	+$3.72M	0.47%	74

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Chilton Capital Management's VRTX Position: Q2 2026 in Review

Chilton Capital Management reduced its Vertex Pharmaceuticals (VRTX) stake by 55% in Q2 2026, selling an estimated $14.2K and leaving 26 shares worth $12.9K. The position accounts for ﹤0.01% of the portfolio, ranked #443.

Chilton Capital Management first reported a position in VRTX in Q3 2014 and has held it in 13 quarters since. The position peaked at $9.11M in Q3 2015. 1,747 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

Chilton Capital Management held 26 shares of Vertex Pharmaceuticals worth $12.9K as of Q2 2026.
Chilton Capital Management sold 32 Vertex Pharmaceuticals shares in Q2 2026, an estimated $14.2K.
Vertex Pharmaceuticals made up ﹤0.01% of Chilton Capital Management's portfolio in Q2 2026, its #443 holding.
Chilton Capital Management first reported a position in Vertex Pharmaceuticals in Q3 2014 and has held it in 13 quarters since.
Chilton Capital Management's Vertex Pharmaceuticals position peaked at $9.11M in Q3 2015.
1,747 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Chilton Capital Management's 13F filing for Q2 2026, filed 4 Aug 2026.